Bladder cancer study halted early: hormone therapy plus chemo tested in just 2 patients
NCT ID NCT05839119
First seen Apr 05, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tested whether adding a drug called degarelix, which lowers testosterone, to standard chemotherapy could help treat muscle-invasive bladder cancer. Only people whose tumors had testosterone receptors were included. The study was stopped early after enrolling just 2 participants, so no clear conclusions can be drawn about the treatment's effectiveness or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02912, United States
Conditions
Explore the condition pages connected to this study.